Novartis to Submit 80 Major Marketing Applications for its Drugs from 2020 to 2022

| By | Novartis

Novartis said Thursday ahead of a meeting with analysts and investors that it expects to submit more than 80 major marketing applications for its drugs from 2020 to 2022 in the US, Europe, Japan and China. CEO Vas Narasimhan remarked “the near term brings yet another catalyst-rich period with pipeline progress across the portfolio that can sustain long-term growth.”

The company noted that it currently has over 160 programmes in clinical development, with more than 500 ongoing clinical studies. “Novartis had a year of breakthrough innovation in 2019, with five potential blockbuster [new molecular entity] approvals,” Narasimhan said, adding that it has another 25 potential blockbuster drugs in development.